Niall Martin, Artios CEO

No­var­tis part­ner Ar­tios bags megaround to dri­ve clin­i­cal work on DNA dam­age re­pair fac­tors

Bio­phar­ma is con­stant­ly on the hunt for the next gen­er­a­tion of tar­get­ed on­col­o­gy drugs to ef­fec­tive­ly wipe out can­cer cells. But to keep those tu­mors gone, biotechs like Ar­tios, now the re­cip­i­ent of a fundrais­ing megaround, are us­ing the cells’ own dam­age re­pair mech­a­nisms against them.

Ar­tios Phar­ma has snagged a $153 mil­lion C round to help dri­ve the UK-based biotech’s lead can­di­dates tar­get­ing DNA dam­age re­pair fac­tors — pro­teins that help knit to­geth­er dam­aged DNA — through the clin­ic, the biotech said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.